Editas’ Novel Sickle Cell Therapeutic Shows Early Promise

Only weeks after announcing a new chief executive officer and chief medical officer, Editas Medicine reported promising early data for its Phase I/II RUBY trial of EDIT-301 for severe sickle cell disease (SCD). The dosing of the first patient was the first time the company’s engineered AsCas12a enzyme has been used to edit human cells in a trial.